Drug Trial Radar · NCT06750276
A Study to Evaluate the Safety, Tolerability, PK, and PD Effects of AZD2389 in Participants With Liver Fibrosis and Compensated Cirrhosis.
Last checked: Nov 19, 2026Latest source record: Jul 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Dec 6, 2024
Primary completion
Jul 28, 2025
Study completion Jul 28, 2025
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Dec 27, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to measure the safety, tolerability, and the way the body absorbs, distributes, and metabolises AZD2389 as compared to placebo in participants with liver fibrosis and compensated cirrhosis. The study will also examine how the drug acts on the body
Conditions
- Liver Fibrosis
- Hepatic Cirrhosis
Interventions
AZD2389Drug
Doses of AZD2389 or placebo will be administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Notable Trends in Laboratory Assessments (Haematology, Coagulation, Clinical Chemistry, Fibrinolysis, and Urinalysis)Time frame: From screening up to and including Day 35
- Clinically Relevant Trends in Vital Signs (Blood Pressure, Pulse Rate, Oxygen Saturation, Body Temperature, and Respiration Rate), and 12-lead Electrocardiogram (ECG)Time frame: From Screening up to and including Day 35
Locations
9 sites in 3 countries. Site status is shown where the registry gives one.
Research Site
Chandler, Arizona
Research Site
Rialto, California
Research Site
Atlanta, Georgia
Research Site
Morehead City, North Carolina
Research Site
Houston, Texas
Research Site
San Antonio, Texas
Research Site
San Antonio, Texas
Research Site
San Juan, Puerto Rico
Research Site
Cambridge, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.